
E-Msion Inc Profile last edited on: 4/24/2023
CAGE: 7JM26
UEI: MQ44SZ4FKNU8
Business Identifier: Electron-based fragmentation in mass spectrometry Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 04
County: Benton
Congr. District: 04
County: Benton
Public Profile
Founded by mass spectrometry researchers affiliated with Oregon State University, E-Msion Inc's ExD Cell is the culmination of over a decade of research and development. With the objective being to advance proteomics research by improving the accessibility of electron-based fragmentation in mass spectrometry, the firm offers a device - designated the ExD Cell - that enables a type of fragmentation, similar to electron-capture dissociation (ECD), as an add-on to virtually any type of mass spectrometer. This unique type of fragmentation produced by the device enables fast, comprehensive characterization of ions without the experimental complexity of other competing technologies on the market today. e-MSion is the first to make ECD technically feasible on instruments that are in the low- to mid-price range. As a result, the device makes ECD more accessible for the masses. The universally-compatible ExD Cell device can give life science researchers the ability to more comprehensively characterize their molecules of interest. ____ In March 2023, it was announced that the firm had been acquired by Agilent Technologies.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $1,078,203 | |
Project Title: Real time optimization of electron-based fragmentation for middle and top-down proteomics in mass spectrometry | ||||
2021 | 1 | NIH | $252,070 | |
Project Title: Advancing native top-down protein analysis with hybrid SID/ECD technology | ||||
2021 | 2 | NIH | $1,716,549 | |
Project Title: Inert Gas Modulation of Electron-Based Fragmentation for Proteomics | ||||
2019 | 2 | NIH | $1,717,650 | |
Project Title: Enabling electron-induced fragmentation in tandem mass spectrometry | ||||
2018 | 2 | NIH | $1,976,788 | |
Project Title: Practical Mass Spectrometry Upgrade for Identifying Fragile Protein Modifications by ECD |
Key People / Management
Joseph S Beckman -- President and CEO
Gary Chow -- Project Manager
Nathan Lopez -- Manufacturing Lead
Joseph Meeuwsen -- Product Manager
Jared Bryan Shaw -- Chief Science Officer
Derrill Sturgeon -- VP of Engineering
Stephanie Sturgeon -- Software Project Manager
Valery G Voinov -- Chief Technology Officer
Gary Chow -- Project Manager
Nathan Lopez -- Manufacturing Lead
Joseph Meeuwsen -- Product Manager
Jared Bryan Shaw -- Chief Science Officer
Derrill Sturgeon -- VP of Engineering
Stephanie Sturgeon -- Software Project Manager
Valery G Voinov -- Chief Technology Officer
Company News
There are no news available.